Ouro Fino Saúde Animal Participações S.A (OFSA3) Fair Value & Analysis
Healthcare · BR · Market cap R$1.4B
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 23 days ago
Share price −0.9% over the past month.
A solid business, screening 113% undervalued on our models.
What matters now
- The price is below even our cautious bear case (R$32.11). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (R$32.11 to R$87.86). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range R$15.26 – R$33.78 · fair‑value band R$32.11 – R$87.86 · the R$26.42 price screens below the R$56.36 fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Ouro Fino Saúde Animal Participações S.A (OFSA3) currently trades at R$26.42, while our model-based Fair Value estimate is R$56.36, implying the stock looks roughly 113.3% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Ouro Fino Saúde Animal Participações S.A generated revenue of R$1.3B at a net margin of 18.8%. Revenue grew 32.1% year over year. It earns a return on equity of 33.3%. Net debt stands at R$239M. Fundamentals as of Jul 17, 2026
Our scenario range runs from R$32.11 (bear case) to R$87.86 (bull case); at R$26.42, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 32% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 113%, OFSA3 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (R$82.95) versus Dividend Discount (R$8.32). Highest evidence: Growth DCF (80).
Notify me when OFSA3 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations.
Full company description
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, products for animal reproduction, and vaccines; and performance-enhancing additives, probiotics, and other veterinary products for cattle, swine, poultry, sheep, horses, and goats, as well as manufacturing services. The company also manufactures veterinary solutions for dogs and cats, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products. In addition, it offers vaccines and other veterinary products for production and companion animals. The company was formerly known as A.H.N.S.P.E. Empreendimentos e Participações S.A. Ouro Fino Saúde Animal Participações S.A. was incorporated in 1987 and is headquartered in Cravinhos, Brazil.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ouro Fino Saúde Animal Participações S.A reported revenue of R$1.2B in FY2025 versus R$905M in FY2021, a compound +7.9%/yr. Reported net income was R$222M in FY2025, compounding +18.2%/yr from FY2021.
Watch OFSA3: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Ouro Fino Saúde Animal Participações S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ouro Fino Saúde Animal Participações S.A (OFSA3) overvalued or undervalued?
What is the fair value of OFSA3?
What is the quality score of OFSA3?
What is the revenue of Ouro Fino Saúde Animal Participações S.A (OFSA3)?
What is the net profit margin of OFSA3?
Does Ouro Fino Saúde Animal Participações S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ouro Fino Saúde Animal Participações S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.